Brenda W. Cooper | Case Comprehensive ...

Dr. Brenda W. Cooper

Claim this profile

Case Western Reserve University

Studies Acute Myeloid Leukemia
Studies Leukemia
11 reported clinical trials
30 drugs studied

Area of expertise

1

Acute Myeloid Leukemia

Brenda W. Cooper has run 6 trials for Acute Myeloid Leukemia. Some of their research focus areas include:

CD33 positive
t(8;21) negative
inv(16) negative
2

Leukemia

Brenda W. Cooper has run 4 trials for Leukemia. Some of their research focus areas include:

CD33 positive

Affiliated Hospitals

Image of trial facility.

Case Western Reserve University

Image of trial facility.

University Hospitals Seidman Cancer Center

Clinical Trials Brenda W. Cooper is currently running

Image of trial facility.

Inotuzumab Ozogamicin + Chemotherapy

for Leukemia

This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a chemotherapy drug called ozogamicin. Inotuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD22 receptors, and delivers ozogamicin to kill them. Chemotherapy drugs, such as \[intervention\], work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving inotuzumab ozogamicin with chemotherapy may work better in treating young adults with B acute lymphoblastic leukemia.

Recruiting

2 awards

Phase 3

3 criteria

Image of trial facility.

Lenalidomide + Dexamethasone +/- Daratumumab

for Multiple Myeloma

This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma.

Recruiting

2 awards

Phase 3

12 criteria

More about Brenda W. Cooper

Clinical Trial Related

7 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 3 Active Clinical Trials

Treatments Brenda W. Cooper has experience with

  • Dexamethasone
  • Cytarabine
  • Ibrutinib
  • VOR33
  • Cyclophosphamide
  • Allopurinol

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Brenda W. Cooper specialize in?

Is Brenda W. Cooper currently recruiting for clinical trials?

Are there any treatments that Brenda W. Cooper has studied deeply?

What is the best way to schedule an appointment with Brenda W. Cooper?

What is the office address of Brenda W. Cooper?

Is there any support for travel costs?